Biogen Inc. Announces New Insights and Data from Alzheimer's Disease Trials at 2025 AAIC, Including Lecanemab and BIIB080 Studies

Reuters
07-22
Biogen Inc. Announces New Insights and Data from Alzheimer's Disease Trials at 2025 AAIC, Including Lecanemab and BIIB080 Studies

Biogen Inc. has announced that it will present new findings at the upcoming 2025 Alzheimer's Association International Conference in Toronto, Canada, from July 27-31. The presentations will include 48-month results from the Clarity AD open-label extension study on LEQEMBI® (lecanemab), offering insights into real-world treatment and a subcutaneous formulation for maintenance dosing. Additionally, Biogen will present baseline characteristics from CELIA, a Phase 2 trial evaluating BIIB080, an investigational antisense oligonucleotide therapy targeting tau. These findings aim to advance the understanding and treatment of Alzheimer's disease. The results are set to be presented during the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497871-en) on July 21, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10